What Is Pardaxin? Definition and What Research Reports

Plain definition

Pardaxin is a small, naturally occurring antimicrobial peptide (AMP) of 33 amino acids that was originally isolated from the milky skin secretion of sole fish of the genus Pardachirus, including the Red Sea Moses sole (Pardachirus marmoratus) and the peacock sole (P. pavoninus), where the secretion is released from glands near the base of the fins. Chemically it belongs to the cationic, amphipathic, helix–hinge–helix family of membrane-active peptides: one face of the molecule is hydrophobic and one is charged, which allows it to partition into lipid bilayers. In the peptide literature the word “pardaxin” is used both for the native fish peptide and for the synthetic versions and sequence variants prepared for laboratory study. It is a research compound rather than an approved medicine, and the published work on it is preclinical — cell culture, artificial membranes, and animal models.

What class of molecule it is

Pardaxin sits in three overlapping categories that researchers use when describing it:

• Antimicrobial (host-defence) peptide — a short, positively charged peptide of the kind many organisms produce as part of innate immunity.
• Pore-forming / membrane-lytic peptide — a peptide whose primary described activity is inserting into and permeabilising lipid bilayers rather than binding a classical receptor.
• Marine-derived peptide — a natural product sourced from a marine organism, a category that is frequently screened for antimicrobial and antitumour activity.

Because of that membrane activity, pardaxin is often grouped alongside better-known lytic peptides such as melittin and magainin in biophysics papers, and it is regularly used as a structural model for studying how amphipathic helices disrupt membranes.

How the term is used in peptide research

Three research uses of the term dominate the published record:

1. As a biophysical model peptide. Solid-state NMR and vesicle-leakage experiments use pardaxin to test competing models of membrane disruption (barrel-stave pores, carpet mechanisms, detergent-like solubilisation).
2. As a candidate anticancer agent in preclinical models. Several groups have tested pardaxin against tumour cell lines and in mouse or veterinary models.
3. As a probe of cell signalling. Its ability to perturb membranes has been used to trigger and study downstream enzymatic and secretory responses in cultured cells.

What the published literature reports

Membrane interaction and mechanism

A solid-state NMR study reported that cholesterol reduced pardaxin’s dynamics within the bilayer and interpreted the peptide’s membrane disruption through a barrel-stave mechanism, in which peptide monomers assemble into a defined transmembrane pore (PMID 19716800). In a complementary biophysical experiment, researchers reported that pardaxin permeabilised lipid vesicles more efficiently by pore formation than by wholesale vesicle disruption (PMID 20159154). Together, the two reports frame pardaxin in the literature as a pore-former whose behaviour depends on the lipid composition — notably cholesterol content — of the target membrane, which is one reason its activity differs between microbial and mammalian membranes.

Tumour cell and animal model work

A 2011 study reported that pardaxin triggered caspase-dependent and reactive oxygen species (ROS)-mediated apoptosis in HT-1080 human fibrosarcoma cells (PMID 22073006). A follow-up report described antitumour activity toward murine fibrosarcoma both in vitro and in vivo (PMID 23015777). Separate work examined oral squamous cell carcinoma and reported anticancer activity against proliferation and tumour growth in vitro and in vivo (PMID 26703631), while a veterinary-oriented study reported potent anti-tumour activity against canine perianal gland adenoma (PMID 25544775). In a different tumour type, researchers reported that pardaxin promoted differentiation and maturation of leukaemic cells through TLR2/MyD88 signalling rather than by direct lysis alone, with an accompanying effect against cell proliferation (PMID 30915150). None of these reports are human clinical trials; all are laboratory and animal studies.

Signalling and other biology

An earlier pharmacology paper reported that pardaxin stimulated phospholipases A2 in PC-12 cells and that these enzymes were involved in the resulting exocytosis (PMID 12023524), which is one of the reasons the peptide is described as a secretagogue in older literature. More recently, a 2022 study in Peptides reported antiosteoporosis effects of pardaxin through regulation of the osteogenesis pathway, extending interest in the peptide beyond antimicrobial and antitumour contexts (PMID 34774923). This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any compound discussed in the scientific literature.

Summary table of the cited literature

Safety and Tolerability: What Studies Report

The verified literature summarised on this page consists of biophysical, cell-culture, animal and veterinary studies; it does not include human clinical safety or tolerability trials, and no human dosing information is available from these sources. Because pardaxin’s described mode of action is membrane permeabilisation, its selectivity between microbial, tumour and normal cells is a recurring question in the mechanistic literature, and the NMR work indicating that cholesterol altered the peptide’s bilayer dynamics is directly relevant to that question (PMID 19716800). Studies that reported apoptosis in tumour cells described it as caspase-dependent and ROS-mediated rather than purely lytic (PMID 22073006), and the leukaemia work reported a signalling-mediated differentiation effect (PMID 30915150). Readers comparing sources should note that findings in cells and animals do not establish safety or effectiveness in people.

Regulatory and terminology notes

• Pardaxin is not an approved drug product in the United States; material described in the scientific literature is handled as a research chemical under research-use-only (RUO) labelling.
• The term may appear with numbered isoform or analogue designations in papers that compare sequence variants; the numbering refers to the specific peptide studied, not to a potency ranking.
• Older toxinology literature sometimes describes pardaxin as an ichthyotoxin or shark-repellent component, reflecting the ecological context of the fish secretion in which it was found rather than a separate molecule.

Related terms

• Antimicrobial peptide (AMP) — the broader class pardaxin belongs to.
• Amphipathic α-helix — the structural feature underlying its membrane activity.
• Barrel-stave model — the pore geometry invoked in the NMR analysis of pardaxin (PMID 19716800).
• Host-defence peptide — an alternative name emphasising innate immune function.

References

• Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells (Marine Drugs, 2011)
• Antiosteoporosis effects of a marine antimicrobial peptide pardaxin via regulation of the osteogenesis pathway (Peptides, 2022)
• Cholesterol reduces pardaxin's dynamics—a barrel-stave mechanism of membrane disruption investigated by solid-state NMR (Biochimica et Biophysica Acta, 2010)
• In Vitro and in Vivo Anticancer Activity of Pardaxin against Proliferation and Growth of Oral Squamous Cell Carcinoma (Marine Drugs, 2015)
• Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma in vitro and in vivo (Marine Drugs, 2012)
• Pardaxin permeabilizes vesicles more efficiently by pore formation than by disruption (Biophysical Journal, 2010)
• Pardaxin stimulation of phospholipases A2 and their involvement in exocytosis in PC-12 cells (Journal of Pharmacology and Experimental Therapeutics, 2002)
• Pardaxin Promoted Differentiation and Maturation of Leukemic Cells via Regulating TLR2/MyD88 Signal against Cell Proliferation (Evidence-Based Complementary and Alternative Medicine, 2019)
• The antimicrobial peptide pardaxin exerts potent anti-tumor activity against canine perianal gland adenoma (Oncotarget, 2015)